Free Trial

Amarin (NASDAQ:AMRN) Stock Rating Upgraded by Wall Street Zen

Amarin logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Amarin from “hold” to “buy,” though the broader analyst consensus remains “sell,” with a $13 target price.
  • Amarin reported quarterly EPS of $0.01, beating the $0.10-per-share loss analysts expected, but revenue of $39.55 million fell short of the $43.76 million consensus estimate.
  • Shares opened at $11.38, near the stock’s one-year low of $11.25 and below its 50-day and 200-day moving averages.
  • Five stocks to consider instead of Amarin.

Amarin (NASDAQ:AMRN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Monday, Wall Street Zen reports.

Several other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. started coverage on shares of Amarin in a research note on Friday, August 21st. They issued an "underweight" rating and a $13.00 price objective on the stock. Zacks Research lowered shares of Amarin from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 3rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Amarin in a report on Thursday, October 15th. One analyst has rated the stock with a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Sell" and a consensus target price of $13.00.

View Our Latest Analysis on AMRN

Amarin Stock Performance

Shares of NASDAQ AMRN opened at $11.38 on Monday. The stock has a fifty day moving average price of $12.53 and a two-hundred day moving average price of $14.14. The firm has a market cap of $239.78 million, a P/E ratio of -11.85 and a beta of 0.81. Amarin has a 1 year low of $11.25 and a 1 year high of $17.31.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.11. The company had revenue of $39.55 million for the quarter, compared to the consensus estimate of $43.76 million. Amarin had a negative return on equity of 0.52% and a negative net margin of 10.87%. On average, research analysts predict that Amarin will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amarin

Institutional investors and hedge funds have recently modified their holdings of the stock. Brooklands Fund Management Ltd increased its stake in Amarin by 23.1% in the 3rd quarter. Brooklands Fund Management Ltd now owns 218,373 shares of the biopharmaceutical company's stock worth $2,839,000 after purchasing an additional 41,048 shares in the last quarter. Steward Partners Investment Advisory LLC raised its holdings in Amarin by 28.8% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 11,479 shares of the biopharmaceutical company's stock worth $149,000 after buying an additional 2,569 shares during the period. R Squared Ltd raised its holdings in Amarin by 190.9% during the 3rd quarter. R Squared Ltd now owns 49,272 shares of the biopharmaceutical company's stock worth $641,000 after buying an additional 32,334 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in Amarin during the 3rd quarter worth about $146,000. Finally, LCM Capital Management Inc lifted its stake in Amarin by 17.1% during the third quarter. LCM Capital Management Inc now owns 60,162 shares of the biopharmaceutical company's stock valued at $782,000 after buying an additional 8,800 shares in the last quarter. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Company Profile

(Get Free Report)

Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health. Its principal product is VASCEPA, a prescription medicine containing icosapent ethyl, an omega-3 fatty acid derivative. In the United States, VASCEPA is approved for use with a statin and other measures to reduce the risk of certain cardiovascular events in eligible adults with elevated triglycerides. It is also approved as an adjunct to diet to lower triglyceride levels in adults with severe hypertriglyceridemia.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amarin Right Now?

Before you consider Amarin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.

While Amarin currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines